Biogen (BIIB) exec Nicole Murphy gets 10,560 RSUs and buys stock

Rhea-AI Filing Summary

BIOGEN INC. executive Nicole Murphy reported a grant of 10,560 restricted stock units and a small open-market share purchase. The restricted stock units were awarded on February 13, 2026 and vest in three equal yearly installments starting on the first anniversary of that grant date. On February 12, 2026 she bought 3 shares of Biogen common stock in an open-market transaction at a price of $195.035 per share. Following these transactions, her direct holdings total 19,611.0408 shares of common stock and 10,560 restricted stock units.

Insider Trade Summary

Net Buyer: 3 shares ($585)

Net Buy 2 txns

Insider Murphy Nicole

Role Head of Pharm Ops and Tech

Bought 3 shs ($585.11)

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	10,560	$0.00	--
Purchase	Common Stock	3	$195.035	$585.11

Holdings After Transaction: Restricted Stock Unit — 10,560 shares (Direct); Common Stock — 19,611.041 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Murphy Nicole

(Last) (First) (Middle)

225 BINNEY STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Head of Pharm Ops and Tech

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		P		3	A	$195.035	19,611.0408	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0	02/13/2026		A		10,560		(1)	02/13/2029	Common Stock	10,560	$0	10,560	D

Explanation of Responses:

1. The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.

	/s/ Wendell Taylor, attorney in fact for Nicole Murphy	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Biogen (BIIB) executive Nicole Murphy report?

Nicole Murphy reported receiving 10,560 restricted stock units and buying 3 Biogen common shares. The RSUs were granted on February 13, 2026, while the share purchase occurred February 12, 2026 at $195.035 per share in an open-market transaction.

How many Biogen (BIIB) restricted stock units were granted to Nicole Murphy?

Nicole Murphy was granted 10,560 restricted stock units of Biogen. These units vest over time in three equal yearly installments, beginning on the first anniversary of the February 13, 2026 grant date, aligning her compensation with longer-term company performance.

What is the vesting schedule for Nicole Murphy’s Biogen (BIIB) RSU grant?

The 10,560 restricted stock units vest in three equal annual installments. Vesting begins on the first anniversary of the February 13, 2026 grant date, meaning one-third vests each year over three years, contingent on continued service and applicable plan terms.

What price did Nicole Murphy pay for the Biogen (BIIB) shares she purchased?

Nicole Murphy purchased 3 shares of Biogen common stock at $195.035 per share. The transaction was an open-market purchase on February 12, 2026, increasing her directly held common stock position as reported in the Form 4 insider filing.

How many Biogen (BIIB) common shares does Nicole Murphy hold after these transactions?

After the reported open-market purchase, Nicole Murphy directly holds 19,611.0408 shares of Biogen common stock. This figure reflects her position following the February 12, 2026 transaction, as disclosed in the Form 4 ownership totals section.

What is Nicole Murphy’s total Biogen (BIIB) equity exposure after the Form 4 events?

Nicole Murphy holds 19,611.0408 Biogen common shares and 10,560 restricted stock units. The RSUs will convert into shares as they vest over three years, while the common shares represent her current directly owned stock position.